Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men
Recent epidemiological studies suggest an association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk of prostate cancer. We evaluated the association between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) and prostate...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 2003-07, Vol.63 (14), p.3991-3994 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3994 |
|---|---|
| container_issue | 14 |
| container_start_page | 3991 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 63 |
| creator | WOODSON, Karen TANGREA, Joseph A POLLAK, Michael COPELAND, Terry D TAYLOR, Philip R VIRTAMO, Jarmo ALBANES, Demetrius |
| description | Recent epidemiological studies suggest an association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk of prostate cancer. We evaluated the association between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) and prostate cancer risk in a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Within the same cohort (using different cases and controls who had sequential serum samples available) we also examined changes in serum IGF-I and IGFBP-3 levels over time by case status. The risk association study included incident prostate cancer cases (n = 100) diagnosed at least 5 years after baseline blood draw (range, 5-12 years; median 9 years) and frequency-matched (4:1) controls. The sequential serum study included all of the prostate cancer cases (n = 21) with prediagnostic (2-3 years before diagnosis) and diagnostic serum available, and pair-matched controls (1:1). An ELISA was used to quantitate serum levels of IGF-I and IGFBP-3 for both studies. The association between IGF-I or IGFBP-3 and prostate cancer risk was assessed using conditional logistic regression, and paired t tests were used to evaluate case-control differences in change in serum analytes over time. We found no significant association between either IGF-I or IGFBP-3 and prostate cancer risk. In a multivariate analysis, we observed an odds ratio of 0.52 (95% confidence interval, 0.23-1.16) for the fourth versus the first quartile of serum IGF-I. Serum IGF-I, but not IGFBP-3, increased significantly over time in cases (18% increase) but not controls (4% decrease; P = 0.02). In contrast to previous reports, we found no evidence to support a causal association between serum IGF-I or IGFBP-3 and the risk of prostate cancer. It is possible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate cancer. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73478123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73478123</sourcerecordid><originalsourceid>FETCH-LOGICAL-h186t-73b688fb00970e12c0f9afdf0b6289e37663ed99d05195ee631965425395a1043</originalsourceid><addsrcrecordid>eNpFkDFPwzAQhSMEoqXwF5AX2CLZcRzbLKiqKFSqxECZI8e5tKaJU2wH1IXfjgVBTPfu9N3pvTtJpoRRkfI8Z6fJFGMsUpbzbJJceP8WW0YwO08mJBOcSllMk68XcEOHjPVDa2zamj2gres_ww41SofeodUd2gxdFJ1ye3AoKgimb_ut0SNzj-bo4Hp_AB3MByAfhvqI-uZnGFQApJXVcVd1vd2ipbHW-B3qwF4mZ41qPVyNdZa8Lh82i6d0_fy4WszX6Y6IIqScVoUQTYWx5BhIpnEjVVM3uCoyIYHyoqBQS1nHgJIBFJTIguUZo5IpgnM6S25_70ZH7wP4UHbGa2hbZaEffMlpzgXJaASvR3CoOqjLgzMx97H8-1gEbkZAea3axsVkxv9zDGPOc0G_AV8Cdf4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73478123</pqid></control><display><type>article</type><title>Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>WOODSON, Karen ; TANGREA, Joseph A ; POLLAK, Michael ; COPELAND, Terry D ; TAYLOR, Philip R ; VIRTAMO, Jarmo ; ALBANES, Demetrius</creator><creatorcontrib>WOODSON, Karen ; TANGREA, Joseph A ; POLLAK, Michael ; COPELAND, Terry D ; TAYLOR, Philip R ; VIRTAMO, Jarmo ; ALBANES, Demetrius</creatorcontrib><description>Recent epidemiological studies suggest an association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk of prostate cancer. We evaluated the association between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) and prostate cancer risk in a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Within the same cohort (using different cases and controls who had sequential serum samples available) we also examined changes in serum IGF-I and IGFBP-3 levels over time by case status. The risk association study included incident prostate cancer cases (n = 100) diagnosed at least 5 years after baseline blood draw (range, 5-12 years; median 9 years) and frequency-matched (4:1) controls. The sequential serum study included all of the prostate cancer cases (n = 21) with prediagnostic (2-3 years before diagnosis) and diagnostic serum available, and pair-matched controls (1:1). An ELISA was used to quantitate serum levels of IGF-I and IGFBP-3 for both studies. The association between IGF-I or IGFBP-3 and prostate cancer risk was assessed using conditional logistic regression, and paired t tests were used to evaluate case-control differences in change in serum analytes over time. We found no significant association between either IGF-I or IGFBP-3 and prostate cancer risk. In a multivariate analysis, we observed an odds ratio of 0.52 (95% confidence interval, 0.23-1.16) for the fourth versus the first quartile of serum IGF-I. Serum IGF-I, but not IGFBP-3, increased significantly over time in cases (18% increase) but not controls (4% decrease; P = 0.02). In contrast to previous reports, we found no evidence to support a causal association between serum IGF-I or IGFBP-3 and the risk of prostate cancer. It is possible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate cancer.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 12873996</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Case-Control Studies ; Humans ; Insulin-Like Growth Factor Binding Protein 3 - blood ; Insulin-Like Growth Factor I - metabolism ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Prospective Studies ; Prostatic Neoplasms - blood ; Randomized Controlled Trials as Topic ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Cancer research (Chicago, Ill.), 2003-07, Vol.63 (14), p.3991-3994</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15007748$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12873996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WOODSON, Karen</creatorcontrib><creatorcontrib>TANGREA, Joseph A</creatorcontrib><creatorcontrib>POLLAK, Michael</creatorcontrib><creatorcontrib>COPELAND, Terry D</creatorcontrib><creatorcontrib>TAYLOR, Philip R</creatorcontrib><creatorcontrib>VIRTAMO, Jarmo</creatorcontrib><creatorcontrib>ALBANES, Demetrius</creatorcontrib><title>Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Recent epidemiological studies suggest an association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk of prostate cancer. We evaluated the association between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) and prostate cancer risk in a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Within the same cohort (using different cases and controls who had sequential serum samples available) we also examined changes in serum IGF-I and IGFBP-3 levels over time by case status. The risk association study included incident prostate cancer cases (n = 100) diagnosed at least 5 years after baseline blood draw (range, 5-12 years; median 9 years) and frequency-matched (4:1) controls. The sequential serum study included all of the prostate cancer cases (n = 21) with prediagnostic (2-3 years before diagnosis) and diagnostic serum available, and pair-matched controls (1:1). An ELISA was used to quantitate serum levels of IGF-I and IGFBP-3 for both studies. The association between IGF-I or IGFBP-3 and prostate cancer risk was assessed using conditional logistic regression, and paired t tests were used to evaluate case-control differences in change in serum analytes over time. We found no significant association between either IGF-I or IGFBP-3 and prostate cancer risk. In a multivariate analysis, we observed an odds ratio of 0.52 (95% confidence interval, 0.23-1.16) for the fourth versus the first quartile of serum IGF-I. Serum IGF-I, but not IGFBP-3, increased significantly over time in cases (18% increase) but not controls (4% decrease; P = 0.02). In contrast to previous reports, we found no evidence to support a causal association between serum IGF-I or IGFBP-3 and the risk of prostate cancer. It is possible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate cancer.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Case-Control Studies</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor Binding Protein 3 - blood</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prospective Studies</subject><subject>Prostatic Neoplasms - blood</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkDFPwzAQhSMEoqXwF5AX2CLZcRzbLKiqKFSqxECZI8e5tKaJU2wH1IXfjgVBTPfu9N3pvTtJpoRRkfI8Z6fJFGMsUpbzbJJceP8WW0YwO08mJBOcSllMk68XcEOHjPVDa2zamj2gres_ww41SofeodUd2gxdFJ1ye3AoKgimb_ut0SNzj-bo4Hp_AB3MByAfhvqI-uZnGFQApJXVcVd1vd2ipbHW-B3qwF4mZ41qPVyNdZa8Lh82i6d0_fy4WszX6Y6IIqScVoUQTYWx5BhIpnEjVVM3uCoyIYHyoqBQS1nHgJIBFJTIguUZo5IpgnM6S25_70ZH7wP4UHbGa2hbZaEffMlpzgXJaASvR3CoOqjLgzMx97H8-1gEbkZAea3axsVkxv9zDGPOc0G_AV8Cdf4</recordid><startdate>20030715</startdate><enddate>20030715</enddate><creator>WOODSON, Karen</creator><creator>TANGREA, Joseph A</creator><creator>POLLAK, Michael</creator><creator>COPELAND, Terry D</creator><creator>TAYLOR, Philip R</creator><creator>VIRTAMO, Jarmo</creator><creator>ALBANES, Demetrius</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20030715</creationdate><title>Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men</title><author>WOODSON, Karen ; TANGREA, Joseph A ; POLLAK, Michael ; COPELAND, Terry D ; TAYLOR, Philip R ; VIRTAMO, Jarmo ; ALBANES, Demetrius</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h186t-73b688fb00970e12c0f9afdf0b6289e37663ed99d05195ee631965425395a1043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Case-Control Studies</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor Binding Protein 3 - blood</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prospective Studies</topic><topic>Prostatic Neoplasms - blood</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WOODSON, Karen</creatorcontrib><creatorcontrib>TANGREA, Joseph A</creatorcontrib><creatorcontrib>POLLAK, Michael</creatorcontrib><creatorcontrib>COPELAND, Terry D</creatorcontrib><creatorcontrib>TAYLOR, Philip R</creatorcontrib><creatorcontrib>VIRTAMO, Jarmo</creatorcontrib><creatorcontrib>ALBANES, Demetrius</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WOODSON, Karen</au><au>TANGREA, Joseph A</au><au>POLLAK, Michael</au><au>COPELAND, Terry D</au><au>TAYLOR, Philip R</au><au>VIRTAMO, Jarmo</au><au>ALBANES, Demetrius</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2003-07-15</date><risdate>2003</risdate><volume>63</volume><issue>14</issue><spage>3991</spage><epage>3994</epage><pages>3991-3994</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Recent epidemiological studies suggest an association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk of prostate cancer. We evaluated the association between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) and prostate cancer risk in a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Within the same cohort (using different cases and controls who had sequential serum samples available) we also examined changes in serum IGF-I and IGFBP-3 levels over time by case status. The risk association study included incident prostate cancer cases (n = 100) diagnosed at least 5 years after baseline blood draw (range, 5-12 years; median 9 years) and frequency-matched (4:1) controls. The sequential serum study included all of the prostate cancer cases (n = 21) with prediagnostic (2-3 years before diagnosis) and diagnostic serum available, and pair-matched controls (1:1). An ELISA was used to quantitate serum levels of IGF-I and IGFBP-3 for both studies. The association between IGF-I or IGFBP-3 and prostate cancer risk was assessed using conditional logistic regression, and paired t tests were used to evaluate case-control differences in change in serum analytes over time. We found no significant association between either IGF-I or IGFBP-3 and prostate cancer risk. In a multivariate analysis, we observed an odds ratio of 0.52 (95% confidence interval, 0.23-1.16) for the fourth versus the first quartile of serum IGF-I. Serum IGF-I, but not IGFBP-3, increased significantly over time in cases (18% increase) but not controls (4% decrease; P = 0.02). In contrast to previous reports, we found no evidence to support a causal association between serum IGF-I or IGFBP-3 and the risk of prostate cancer. It is possible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate cancer.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>12873996</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 2003-07, Vol.63 (14), p.3991-3994 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73478123 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Biological and medical sciences Biomarkers, Tumor - blood Case-Control Studies Humans Insulin-Like Growth Factor Binding Protein 3 - blood Insulin-Like Growth Factor I - metabolism Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Prospective Studies Prostatic Neoplasms - blood Randomized Controlled Trials as Topic Tumors of the urinary system Urinary tract. Prostate gland |
| title | Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A27%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20insulin-like%20growth%20factor%20I:%20Tumor%20marker%20or%20etiologic%20factor?%20A%20prospective%20study%20of%20prostate%20cancer%20among%20Finnish%20men&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=WOODSON,%20Karen&rft.date=2003-07-15&rft.volume=63&rft.issue=14&rft.spage=3991&rft.epage=3994&rft.pages=3991-3994&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E73478123%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73478123&rft_id=info:pmid/12873996&rfr_iscdi=true |